Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Financial Results

DANAHER CORP /DE/ Shares Rise 6% in 9 Days Since Financial Results

Danaher Corp Reports 36% Net Income Growth in Q3 2026 on Robust Revenue Gains

+6.34% in 9 days $224.24 when we broke this story → $238.46 peak on 30 Oct 2026

Danaher Corporation achieved a 36.0% year-over-year increase in net income for the third quarter of 2026, supported by strong revenue growth and aggressive acquisition activity. The company deployed $9.9 billion for cash acquisitions in the first nine months of the year, significantly expanding its footprint in the life sciences and diagnostics sectors.

Analysis, analyzing, beaker, biochemistry. Stock photo illustrating Danaher's financial results story.
DANAHER CORP /DE/ · Photo: ckstockphoto / Pixabay
Results at a glance · $ Million
Metric Q3-26Q3-25
Revenue 6,5546,053
Gross Profit 3,8373,523
Pretax Income 1,1321,076
Net Income 1,235908.00
Diluted EPS 1.751.27
Net Income YoY
+36.0%

Key highlights

  • Quarterly revenue rose to $6,554 million from $6,053 million in the prior year
  • Net income surged 36.0% year-over-year to reach $1,235 million
  • Diluted earnings per share increased to $1.75 compared to $1.27 in Q3 2025
  • Gross profit climbed to $3,837 million, reflecting sustained operational efficiency
  • Management raised full-year 2026 adjusted diluted EPS guidance to $8.57–$8.62

How the Period Went

Danaher reported a significant expansion in its financial performance for the third quarter of 2026. Revenue climbed to $6,554 million, up from $6,053 million in the same period last year, marking a consistent upward trend following revenues of $6.00 billion in the first quarter and $6.30 billion in the second quarter. Net income experienced a substantial 36.0% increase to $1,235 million, compared to $908.00 million previously, while diluted earnings per share rose to $1.75 from $1.27. These results were bolstered by a gross profit of $3,837 million, reflecting the company's ability to scale operations effectively alongside its increasing revenue base.

Margins and Profitability

Profitability metrics remained robust as the company navigated a period of intense capital deployment. While pretax income rose to $1,132 million from $1,076 million, the sharper rise in net income suggests a favorable impact from continuing operations and tax positioning. The company’s acquisition strategy was a primary driver of balance sheet evolution, with $9.9 billion spent on cash acquisitions during the first nine months of 2026. This activity significantly increased goodwill and intangible assets, which management leverages to enhance long-term margins. Net earnings from continuing operations for the nine-month period reached $3.1 billion, up from $2.4 billion in the prior year.

Business Overview

As a global science and technology leader, Danaher operates primarily within the Biotechnology, Life Sciences, and Diagnostics segments. The company provides essential tools, consumables, and software that support the development of life-saving therapies and clinical diagnostics. Serving diverse end markets including pharmaceutical companies, hospitals, and research institutions, Danaher utilizes the Danaher Business System (DBS) to drive continuous improvement. This operational framework allows the company to integrate complex acquisitions, such as those executed this year, while maintaining a focus on high-recurring revenue streams from consumables, which provide stability against broader macroeconomic fluctuations in capital equipment spending.

Financial Context and Industry Landscape

With a market capitalization of $157.6 billion and a P/E ratio of 39.97, Danaher maintains a premium valuation reflective of its leadership in the healthcare sector. The company’s RSI of 56.1 indicates a stable technical position following a 10.21% price increase over the last quarter. In the broader industry, Danaher faces a competitive landscape alongside peers like Thermo Fisher Scientific, where demand for bioprocessing and genomic tools remains a primary growth engine. Danaher’s backlog, which stood at approximately $7.5 billion as of June 26, 2026, according to SEC filings, provides visibility into future revenue as the sector adapts to evolving R&D budgets.

DANAHER CORP /DE/ share price · last month
Line chart of DANAHER CORP /DE/'s share price over the last month, from $224.43 on 19 Oct → $229.91 on 16 Nov; our story on 21 Oct at $224.24.

Up 2.5% since our story on 21 Oct: $224.24 when we broke it → $229.91 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$224.43
20 Oct$224.24
21 Oct$233.86
22 Oct$229.75
23 Oct$230.50
26 Oct$232.97
27 Oct$232.00
28 Oct$234.07
29 Oct$236.98
30 Oct$232.23
2 Nov$227.97
3 Nov$230.11
4 Nov$234.93
5 Nov$226.34
6 Nov$230.25
9 Nov$235.12
10 Nov$236.11
11 Nov$235.31
12 Nov$232.16
13 Nov$233.02
16 Nov$229.91
Recent quarters and guidance
DateAnnouncementAmount
21 Jul 2026Q2 2026 revenuesSource: prnewswire.com$6.30 Billion
21 Jul 2026Full-year 2026 adjusted diluted EPS guidance of $8.45 to $8.60Source: investors.danaher.com–
21 Apr 2026Q1 2026 revenuesSource: prnewswire.com$6.00 Billion
21 Apr 2026Full-year 2026 adjusted diluted EPS guidance raisedSource: prnewswire.com–
DANAHER CORP /DE/ · financial snapshot
Share price$224.24
Market cap$157.6B
Revenue (annual)$24.6B
P/E (TTM)40.0×
1-month price change+6.06%
SectorHealthcareDiagnostics & Research

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Danaher Corporation announcing third quarter 2026 financial results.

Read the filing ↗

Track DANAHER CORP /DE/ live

Get the next DANAHER CORP /DE/ SEC filing seconds after it lands.

More in Results & Earnings

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.